FindTrial
Sign In

A Clinical Trial to Study the Efficacy of Extended Intravenous Steroids in Acute Severe Ulcerative Colitis

The Role of Extended Intravenous Steroid Therapy in Partial Responders of Acute Severe Ulcerative Colitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/02/050124
Enrollment
20
Registered
2023-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K51- Ulcerative colitis

Interventions

Intervention1: Intravenous Hydrocortisone administration: Intravenous Hydrocortisone 100milligrams given every 6 th hourly for a duration of 10 days in Partial Responders of Acute Severe Ulcerative Co

Sponsors

GB Pant Institute Of Post Graduate Medical Education and Research
Lead Sponsor
Dr Ashok Dalal
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients With Acute Severe Ulcerative Colitis as defined by Truelove and Witts criteria

Exclusion criteria

Exclusion criteria: Toxic Megacolon Colorectal Malignancy Pregnancy Clostridium Difficle Infection Cytomegalovirus Infection Any other Superimposed Infection

Design outcomes

Primary

MeasureTime frame
To Find the Proportion of Patients Who Respond to Extended Therapy of Intravenous SteroidsTimepoint: Response to Intravenous Steroids will be assessed on Day 1,Day3,Day 5,Day 7 and Day 10—

Secondary

MeasureTime frame
To Study the Proportion of Patients Requiring Rescue Therapies or Surgery at Three MonthsTimepoint: Three months—

Countries

India

Contacts

Public ContactDr Ashok Dalal

GB Pant Institute of Post Graduate Medical Education and Research

ashok.dalal83@gmail.com9718599219

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026